Back to search

Article

The Percentage of ALK-Positive Cells and the Efficacy of First-Line Alectinib in Advanced Non-small Cell Lung Cancer: Is it a novel factor for stratification? (Turkish Oncology Group Study)

2022-04-28

Abstract excerpt

<h4>Introduction: </h4> Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive tumor cells in patient groups receiving crizotinib might affect outcomes. This study aimed to investigate whether the percentage of ALK-positive cells had a predictive ef...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
50e141ec-5660-53a3-8eae-a52e9c695614
DOI
10.21203/rs.3.rs-1583429/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Percentage of ALK-Positive Cells and the Efficacy of First-Line Alectinib in Advanced Non-small Cell Lung Cancer: Is it a novel factor for stratification? (Turkish Oncology Group Study)DOI 10.21203/rs.3.rs-1583429/v1
The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.Semantic proximity
Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.Semantic proximity
Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity
Mixed responses to first‐line alectinib in non‐small cell lung cancer patients with rare ALK gene fusions: A case series and literature reviewSemantic proximity
Levels of Pretreatment Blood Lipids are Prognostic Factors in Advanced NSCLC Patients Treated with AnlotinibSemantic proximity
Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.Semantic proximity
[Relationship between expression of anaplastic lymphoma kinase in pleural effusion and clinicopathological features of patients with lung adenocarcinoma and the response to crizotinib].Semantic proximity
Alectinib for treatment of ALK-positive non-small-cell lung cancer.Semantic proximity
Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective change.Semantic proximity
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX StudySemantic proximity
A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation.Semantic proximity
The Neutrophil-to-Lymphocyte Ratio as a Prognostic Indicator in Head and Neck Cancer: A Systematic Review and Meta-AnalysisSemantic proximity
Select a neighboring publication to make it the new centre.